Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Operating Leases (2019 - 2023)

Spyre Therapeutics (SYRE) has disclosed Operating Leases for 5 consecutive years, with $3.8 million as the latest value for Q1 2023.

  • For the quarter ending Q1 2023, Operating Leases fell 14.42% year-over-year to $3.8 million, compared with a TTM value of $3.8 million through Mar 2023, down 14.42%, and an annual FY2022 reading of $4.0 million, down 13.11% over the prior year.
  • Operating Leases was $3.8 million for Q1 2023 at Spyre Therapeutics, down from $4.0 million in the prior quarter.
  • Across five years, Operating Leases topped out at $5.1 million in Q4 2020 and bottomed at $372000.0 in Q1 2019.
  • Average Operating Leases over 5 years is $4.3 million, with a median of $4.7 million recorded in 2020.
  • The sharpest move saw Operating Leases skyrocketed 1194.35% in 2020, then decreased 14.42% in 2023.
  • Year by year, Operating Leases stood at $4.7 million in 2019, then grew by 8.85% to $5.1 million in 2020, then decreased by 10.16% to $4.6 million in 2021, then fell by 13.11% to $4.0 million in 2022, then decreased by 4.52% to $3.8 million in 2023.
  • Business Quant data shows Operating Leases for SYRE at $3.8 million in Q1 2023, $4.0 million in Q4 2022, and $4.2 million in Q3 2022.